W. Wolfgang Fleischhacker

from Wikipedia, the free encyclopedia
W. Wolfgang Fleischhacker (2017)

Walter Wolfgang Fleischhacker (born April 29, 1953 in Baden near Vienna ) is an Austrian psychiatrist and psychotherapist and university professor at the Medical University of Innsbruck . In May 2017 he was elected by the University Council as the successor to Helga Fritsch for a four-year term as rector of the university, he took office on October 1, 2017.

Life

Fleischhacker studied medicine at the University of Innsbruck and worked among other things at the Bispebjerg Hospital in Copenhagen . In 1978 he received his doctorate in general medicine from the University of Innsbruck. From 1979 he worked as a university assistant in the departments of psychiatry and neurology at the Medical University of Innsbruck. In 1987 he was awarded a Fulbright Travel Fellowship and spent 18 months as a research fellow in the Department of Psychiatric Research at Hillside Hospital and at the Albert Einstein College of Medicine in New York City . He then completed his habilitation on the subject of pharmacoepidemiology of benzodiazepines for psychiatry and from 1989 worked as a senior physician at the University Clinic for Psychiatry at Innsbruck University. In 1990 he completed his training as a specialist in psychiatry. Since 1992 he has been a psychotherapist specializing in behavioral therapy.

In 1993 he was appointed professor at the Clinical Department for Biological Psychiatry at the Medical Faculty of the University of Innsbruck. From 1994 he also headed the Department of Biological Psychiatry there. From 1999 to 2003 he was a member of the board of directors of the Institute for Communication in Professional Life and Psychotherapy at the Leopold-Franzens University Innsbruck. From 2008 to 2017 he was director of the University Clinic for Biological Psychiatry and Managing Director of the Department of Psychiatry and Psychotherapy at the Medical University of Innsbruck .

In addition to his actual teaching duties, he was visiting professor at the Weill Medical College of Cornell University in New York, Keio University School of Medicine in Tokyo and at the Vienna School for Clinical Research. From 2002 to 2005 he was President of the Austrian Society for Psychiatry and Psychotherapy (ÖGPP) and from 2006 to 2010 Vice President of the International College of Neuropsychopharmacology (CINP). Since 1997 he has been chairman of the European Group for Research in Schizophrenia (EGRIS). In 2006 he became only the second Austrian Foreign Corresponding Fellow of the American College of Neuropsychopharmacology.

Awards

In 2005 he was awarded the Austrian Cross of Honor for Science and Art . In 2006 he became an honorary member of the World Psychiatric Association and in 2004 honorary president of the Austrian Schizophrenia Society (ÖSG).

Research priorities

Fleischhacker initially dealt with addiction research and aspects of clinical psychopharmacology in different areas. After his research stay in the USA, he has focused on psychopharmacology and schizophrenia for around three decades . As part of his research focus, he advised the Austrian and European drug approval authorities and was involved in projects of the World Health Organization (WHO) as well as in a leading role in projects of the World Psychiatric Association (WPA). He became known in professional circles, among other things, through the largest EU schizophrenia treatment study to date on treatment discontinuation in schizophrenia first-time patients ( European First Episode Schizophrenia Trial, EUFEST ), which he planned and directed together with his Dutch colleague René Kahn. Fleischhacker is also on the Executive Board of the FP7 EU research project Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) . This is a large-scale study to optimize therapy in the same group of patients. He is also Principal Investigator of the Europe-wide EULAST project ( European Long-Acting Antipsychotics in Schizophrenia Trial ). Here, for the first time, the effectiveness of depot drugs in the long-term treatment of schizophrenia is evaluated in a large-scale naturalistic study.

Positions

In the context of therapeutic schizophrenia research, W. Wolfgang Fleischhacker advocates the use of new antipsychotics as the gold standard for schizophrenia patients. He takes the position that modern drugs combined with psychosocial treatment results lead to fewer discontinuations and significantly improve treatment.

Fonts

  • with M. Lambert, E. Karamatskos, D. Naber: Pharmacotherapy of Schizophrenia. In: V. Voderholzer, F. Hohagen (Hrsg.): Therapy of mental illnesses. 13th edition. Urban & Fischer / Elsevier, 2018, ISBN 978-3-437-24909-9 , pp. 93–124.
  • with H. Hinterhuber (Ed.): Textbook of Psychiatry . Springer, Stuttgart 2012, ISBN 978-3-211-89865-9 .
  • with S. Miyamoto: Pharmacologic Treatment of Schizophrenia. In: JA Lieberman, RM Murray (Eds.): Comprehensive Care of Schizophrenia. Oxford University Press, 2012, ISBN 978-0-19-538801-5 , chapter 5.
  • with IP Stolerman (Ed.): Encyclopedia of Schizophrenia . Springer-Verlag, 2011, ISBN 978-1-907673-17-7 .
  • with S. Miyamoto, DB Merrill, JA Lieberman, SR Marder: Antipsychotic Drugs. In: A. Tasman, J. Kay, JA Lieberman, MB First, M. May (Eds.): Psychiatry. 3. Edition. Wiley, New York 2008, ISBN 978-0-470-06571-6 , chapter 102.
  • Pharmacotherapy of schizophrenic disorders. In: H. Helmchen, F. Henn, H. Lauter, N. Sartorius (eds.): Schizophrenics and affective disorders. (= Contemporary psychiatry. Volume 5). 4th edition. Springer-Verlag, 2000, ISBN 3-540-65802-5 , pp. 209-242.

Web links

Individual evidence

  1. ↑ derStandard.at: Wolfgang Fleischhacker is the new Rector of the Med-Uni Innsbruck . Article dated May 3, 2017, accessed September 17, 2017.
  2. ↑ Recognition of special merits. myPoint; Retrieved March 25, 2015.
  3. ↑ Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial . In: The Lancet , Volume 371, No. 9618, March 29, 2008, pp. 1085-1097.
  4. ↑ European Long-acting Antipsychotics in Schizophrenia Trial (EULAST) . ClinicalTrials.gov, accessed March 25, 2015.
  5. ↑ Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomized, double-blind, controlled trial. In: The Lancet Journal. March 2017, accessed October 2018 .
  6. ↑ Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. In: Lancet Psyciatry. August 2018, accessed October 2018 .
  7. ↑ W. Wolfgang Fleischhacker: The long ‐ term treatment of schizophrenia with antipsychotics: a perennial debate. In: World Psychiatry. June 2018, accessed October 2018 .
  8. ^ WW Fleischhacker et al.: Schizophrenia - Time to Commit to Policy Change . In: Schizophrenia Bulletin. Vol. 40 Suppl. No 3, 2014.
personal data
SURNAME Fleischhacker, W. Wolfgang
ALTERNATIVE NAMES Fleischhacker, Walter Wolfgang
BRIEF DESCRIPTION Austrian psychiatrist and psychotherapist as well as university professor
DATE OF BIRTH April 29, 1953
PLACE OF BIRTH Baden near Vienna